Abacus Health Products

Abacus Health Products in its going public transaction by way of a reverse takeover, US$15 million concurrent financing and listing on the Canadian Securities Exchange

Client

Abacus Health Products, Inc.

Value

US$15 million

Service

Mergers and Acquisitions

Date Closed

January 2019

Lead Office

Montréal


On January 29, 2019, Abacus Health Products, Inc. (“Abacus”), a Delaware corporation, completed its previously announced going public transaction by way of a reverse takeover of an Ontario corporation formerly known as World Wide Inc. and renamed Abacus Health Products, Inc. In connection with the transaction, Abacus completed a private placement for gross proceeds of US$15 million. The subordinate voting shares of the resulting issuer became listed on the Canadian Securities Exchange following the closing of the transaction.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) topical pain-relieving medications registered with the U.S. Food and Drug Administration which contain CBD, a cannabinoid-rich hemp extract.

Osler, Hoskin & Harcourt LLP represented Abacus with a team consisting of Eric Levy, Jason Comerford, Bastien Gauthier, Jie Chai, Jean-Philippe Bertrand (Corporate), Manon Thivierge and Kevin Colan (Tax).

 


Team
Eric M. Levy
Key Contact

Eric M. Levy

Partner, Corporate

Bastien  Gauthier

Bastien Gauthier

Partner, Corporate

Jason  Comerford

Jason Comerford

Partner, Corporate

Jie Chai

Jie Chai

Associate, Corporate

Jean-Philippe Bertrand

Jean-Philippe Bertrand

Associate, Corporate

Manon Thivierge

Manon Thivierge

Partner, Taxation

Kevin Colan

Kevin Colan

Counsel, Taxation